+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tourette Syndrome Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 113 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896034
The global Tourette syndrome market is expanding at a rapid pace due to the consistent efforts of several organizations to increase awareness regarding the disease among patients.

The major factors driving the growth of the market is increasing cases of Tourette syndrome all across the world. As per the data of the CDC study, 1 of every 360 (0.3%) children 6-17 years of age in the US have received a diagnosis of TS, which is about 138,000 children. Also among children diagnosed with TS, 37% have been reported as having moderate or severe forms of the condition. In addition, it has been found that boys are three to five times more likely to have TS than girls. Apart from the rising cases of Tourette syndrome, increasing focus on Tourette syndrome research is anticipated to contribute significant growth to the studied market.

In addition, the increase in research and development, as well as health care infrastructure globally, drives the Tourette’s syndrome treatment market.

Key Market Trends

Antipsychotic are Expected to Dominate the Tourette Syndrome Treatment Market

Antipsychotic drugs are expected to hold the largest market share due to their ability to treat tics to a greater extent as compared to non-antipsychotic drugs. Antipsychotic drugs were developed for the treatment of schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine specifically by blocking dopamine receptors, mainly the D2 receptor. The robust therapeutic effect of antipsychotics is one of the significant factors driving the growth of the Tourette's syndrome treatment market.

However, future collaborations among clinical sites with Tourette syndrome expertise employing high-quality study design might clarify the role of atypical antipsychotics for the treatment of TS in a better way. The dopamine antagonists may lead to the most reliable treatment response but also can cause severe side effects.

North America Dominates the Tourette Syndrome Treatment Market

North America is found dominating the Tourette Syndrome market owing to high incidences of Tourette syndrome, a highly aware population, advanced healthcare infrastructure, and favorable government initiatives.

According to the CDC data, there are about 140,000 children aged 6 to 17 years in the United States that has ever been diagnosed with TS. The CDC is also found working with the Tourette Association of America to increase access to CBIT (Comprehensive Behavioral Intervention for Tics), provide education and outreach efforts, improve acceptance and lessen stigma through the Tourette Association Youth Ambassador Program and also offer resources to help individuals and families living with Tourette including school resources. In addition, the increase in research & development expenditure and activities and entry of new therapeutics into the market is anticipated to boost the Tourette syndrome market in the forecast period.

Competitive Landscape

Tourette Syndrome Treatment market is very competitive with most of the players competing to increase market shares. The rising competition, rapid technological advancements, focus on research is key factors that have a strong impact on the market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of Tourette Syndrome
4.2.2 Rising Focus on Tourette Syndrome Research
4.3 Market Restraints
4.3.1 Lack of Awareness in Developing Region
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 Product
5.1.1 Antipsychotics
5.1.2 Non Antipsychotics
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AstraZeneca Plc
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Mylan NV
6.1.4 Otsuka Holdings Co. Ltd.
6.1.5 Pfizer Inc.
6.1.6 Reviva Pharmaceuticals Inc.
6.1.7 Auspex Pharmaceuticals, Inc.
6.1.8 Catalyst Pharmaceutical

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Inc.
  • Auspex Pharmaceuticals, Inc.
  • Catalyst Pharmaceutical